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Introduction: The lipid messenger phosphatidic acid (PA) plays a critical role in the stimulation of mTOR signaling.
However, the mechanism by which PA stimulates mTOR is currently unknown. Therefore, the purpose of this study
was to compare the effects of various PA precursors and phospholipids on their ability to stimulate mTOR signaling
and its ability to augment resistance training-induced changes in body composition and performance.
Methods: In phase one, C2C12 myoblasts cells were stimulated with different phospholipids and phospholipid
precursors derived from soy and egg sources. The ratio of phosphorylated p70 (P-p70-389) to total p70 was then
used as readout for mTOR signaling. In phase two, resistance trained subjects (n = 28, 21 ± 3 years, 77 ± 4 kg,
176 ± 9 cm) consumed either 750 mg PA daily or placebo and each took part in an 8 week periodized resistance
training program.
Results: In phase one, soy-phosphatidylserine, soy-Lyso-PA, egg-PA, and soy-PA stimulated mTOR signaling, and the
effects of soy-PA (+636%) were significantly greater than egg-PA (+221%). In phase two, PA significantly increased
lean body mass (+2.4 kg), cross sectional area (+1.0 cm), and leg press strength (+51.9 kg) over placebo.
Conclusion: PA significantly activates mTOR and significantly improved responses in skeletal muscle hypertrophy,
lean body mass, and maximal strength to resistance exercise.
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Increasing or maintaining skeletal muscle mass is an im-
portant target for a variety of populations ranging from
athletes to the elderly. Skeletal muscle mass is largely
dependent upon muscle protein synthesis (MPS), and a
protein kinase called the mechanistic target of rapamy-
cin (mTOR) has been widely recognized as a key regula-
tor of muscle growth. Specifically, elevations in energy
status [1-3], amino acids [4,5], and growth factors [6,7]
can increase MPS through an mTOR-dependent me-
chanism. Furthermore, several studies have also shown
that signaling by mTOR is required for mechanically-
induced increases in MPS and the ultimate hypertrophic
response [8-11].* Correspondence: jmwilson@ut.edu
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unless otherwise stated.Phosphatidic acid (PA) is a diacyl-glycerophospholipid,
in which two fatty acids and a phosphate group are cova-
lently bonded to a glycerol molecule through ester link-
ages. PA can act as a signaling lipid, it is a precursor for
the biosynthesis of other lipids, and it is a major constitu-
ent of cell membranes. Recent studies have shown that
mechanical stimuli can induce an increase in the intracel-
lular levels of PA and that the increase in intracellular PA
contributes to the activation of mTOR-dependent signa-
ling events such as ribosomal S6 kinase 1 (p70) threonine
389 phosphorylation (P-p70-389) [12]. It has also been
shown that PA can directly bind to the FKBP12 · rapamy-
cin binding (FRB) domain of mTOR, and in doing so, it
activates mTOR signaling [13,14]. It has also been shown
that exogenous sources of PA can promote the activation
of mTOR signaling, yet the effects of exogenous PA ap-
pear to be driven through multiple mechanisms. For ex-
ample, Winter and colleagues [15] have demonstrated that
the exogenous addition of PA to fibroblasts results in the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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that is dependent on PA being metabolized to lysopho-
sphatidic acid (LPA) and activating LPA family receptors.
Furthermore, this study demonstrated that the activation
of LPA receptors induces mTOR signaling via an ERK-
dependent mechanism. Alternatively, You et al. [14] have
shown that passively stretching skeletal muscles leads to
an increase in intracellular PA and mTOR signaling and
that the activation of mTOR signaling occurs through an
ERK-independent mechanism. Collectively, these findings
suggest that the exogenous provision of PA and mecha-
nical stimuli can activate mTOR signaling through distinct
pathways, and it is possible that the activation of these dis-
tinct pathways could have additive effects on mTOR
signaling.
While PA plays a critical role in the stimulation of
mTOR signaling and an increase in PA is sufficient for the
activation of mTOR signaling, the exact mechanism by
which PA stimulates mTOR is currently unconfirmed; al-
though, it is very likely that PA primarily mediates its ef-
fects via direct binding to mTOR [13,14]. PA can be
synthesized from a variety of reactions via multiple reac-
tants, but it is not clear if other precursors (glycerol-3-
phosphate (G3P), LPA or diacylglycerol (DAG)), or the
addition of head groups to the PA molecule (phospha-
tidylcholine (PC), phosphatidylserine (PS), phosphati-
dylethanolamine (PE) or phosphatidylinositol (PI)), have a
similar ability to activate mTOR signaling. Moreover,
different sources of PA (soy, egg) can have varying degrees
of unsaturated or saturated fatty acid chains and this can
influence the behavior of PA. Specifically, it has been sug-
gested that two saturated fatty acids will promote storage,
but one saturated and one unsaturated fatty acid will pro-
mote signaling [16].
We have previously examined the absorption kinetics of
1.5 g PA and observed an increase in plasma concentra-
tion after 30 minutes. PA concentrations appear to plateau
between 1 and 3 hours following ingestion while peaking
at 3 hours following ingestion. After 7 hours, PA concen-
trations remained elevated. In addition, LPA demonstrated
a bimodal absorption kinetic with plasma concentration
peaking at 1 hour, returning to baseline at 2 hours, and
peaking again at 3 hours [17]. Thus, exogenous elevations
of PA may be provided through oral supplementation,
while endogenous production could be fostered through a
resistance training stimulus. Theoretically, the combin-
ation of the two could result in greater skeletal muscle
hypertrophy than resistance training alone. However, to
date, only one study has investigated the combination of
oral PA supplementation combined with resistance trai-
ning (RT). Specifically, Hoffman et al. [18] concluded that
it is very likely that PA supplementation in humans under-
going progressive RT results in greater increases in squat
strength and lean mass over the placebo. However, it islikely that this study was underpowered. Moreover, sub-
jects in this pilot study were not supervised during RT. Fi-
nally, while the authors looked at indices of hypertrophy
such as lean body mass, no direct measures of skeletal
muscle hypertrophy were taken. Therefore, the results of
whether or not PA supplementation enhances skeletal
muscle hypertrophy were inconclusive. Thus, the purpose
of this study was to compare the effects of various PA pre-
cursors on their ability to stimulate mTOR signaling and
determine if any other phospholipid species are also
capable of stimulating mTOR signaling. Following the ini-
tial investigation, we performed a double-blind, placebo-
controlled study that was designed to assess the effects of
orally administered PA on skeletal muscle hypertrophy,
strength, and power when consumed during a periodized
RT program. We hypothesized that PA supplementation
would lead to increased improvements in strength, ske-
letal muscle hypertrophy, and power.
Methods
Phase 1 (cell culture tests)
C2C12 myoblasts (ATCC; Manassas, VA, USA) were plated
at approximately 30% confluence and grown for 24 hours
in 10% FBS High Glucose DMEM with antibiotics
(100 μg/ml streptomycin and 100 U/ml penicillin; Sigma-
Aldrich; St. Louis, MO, USA). At 16 hours prior to the
experiment, myoblasts cells were switched to serum free
high glucose DMEM (no antibiotics) and were approxi-
mately 70% confluent at the time of the experiment. All
stimulants were dissolved in chloroform to yield a concen-
tration of 10 mg/mL, with the exception of DAG which
was dissolved at 2 mg/mL and G3P which was dissolved
at 6 mg/mL. Each stimulant was then dried with a stream
of nitrogen gas and resuspended in PBS to obtain either
20 or 60 nmol/100 μL, such that 100 μL added to 2 mL of
media resulted in 10 or 30 μM respectively. Accordingly,
cells were stimulated for 20 minutes with vehicle (Control;
100 μL of PBS) 10 or 30 μM of soy-derived (S) phospha-
tidylserine (S-PS, SerinAid®, Chemi Nutra, White Bear
Lake, MN, USA), phosphatidylinositol (S-PI), phosphati-
dyl-ethanolamine (S-PE), phosphatidylcholine (S-PC), PA
(S-PA, Mediator®, Chemi Nutra, White Bear Lake,
MN, USA), lysophosphatidic acid (S-LPA), diacylglycerol
(DAG), glycerol-3-phosphate (G3P), or egg-derived PA
(E-PA). Cells were then harvested in lysis buffer (40 mM
Tris, pH 7.5; 1 mM EDTA; 5 mM EGTA; 0.5% Triton
X-100; 25 mM β-glycerophosphate; 25 mM NaF; 1 mM
Na3VO4; 10 μg/mL leupeptin; and 1 mM PMSF) and sub-
jected to immunoblotting with anti-phospho-p70 S6
Kinase (Thr389; Cell signaling #9234; 1:1000; Danvers, MA,
USA) as previously described [19]. Once the appropriate
image was captured, membranes were stripped for 30 mi-
nutes in stripping buffer (100 mM β-Mercaptoethanol, 2%
SDS, 62.5 mM Tris HCL pH 6.8) maintained at 50°C.
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dered milk in TBST for 1 h, and then immunoblotted with
anti-p70 S6 Kinase (cell signaling #2708, 1:2000; Danvers,
MA, USA). Once the appropriate image was captured, the
membranes were stained with Coomassie Blue to verify
equal loading in all lanes. Densitometric measurements
were performed by determining the density of each band
using the public domain ImageJ software (U.S. National
Institutes of Health, Bethesda, MD, USA; http://rsb.info.nih.
gov/nih-image/). The ratio of P-p70-389 to total p70 was
used as readout for mTOR signaling. C2C12 myoblasts were
chosen, as it has previously been established that changes
in P-p70-389 phosphorylation are a valid marker of PA in-
duced changes in mTOR signaling [20].
Phase 2 (human efficacy study)
Thirty-four males were recruited from the University of
Tampa to participate in this study. Twenty eight males
(21 ± 3 years, 77 ± 7 kg, 176 ± 9 cm) were used for data
analysis. Three subjects elected to discontinue their par-
ticipation prior to beginning the intervention, citing a
more demanding schedule than they had anticipated; two
subjects ceased participation, claiming the resistance
training protocol was too onerous for them to complete;
and one subject was removed from data analysis due to a
failure to comply with the prescribed diet. Subjects were
equally divided into the PA (n = 14, 78 ± 9 kg, 177 ± 7 cm)
and PLA (n = 14, 76 ± 6 kg, 175 ± 11 cm) groups. All par-
ticipants were required to abstain from consuming any
muscle-building supplements (e.g. creatine) for 1 month
prior to pretest measures, be non-smokers, have RT ex-
perience of no less than one year, and have participated in
RT at least three days per week for the past six months to
be included in this study. Participants were allowed,
although not provided with, multivitamin and protein
powder supplementation during the month prior to the
initiation of the study. Participants were carefully matched
according to their lean body mass (LBM), rectus femoris
cross sectional area (CSA), and leg press 1-repetition-
maximum (1RM), and they were then equally divided into
either the PA or placebo (PLA) groups. Measures of leg
press and bench press 1RM, LBM, fat mass, total mass,
and CSA were taken prior to, and following, the RT
protocol.
RT occurred three days per week with 48–72 hours
between RT sessions. Each body part was trained 1–2
times per week following a daily undulating periodized
scheme. Each participant performed a 5 RM for each ex-
ercise prior to the first four weeks with the exception of
the bench press and leg press, in which true 1RM values
were determined. 5 RM testing was repeated at the end
of week 4 for the new exercises. The 1RM testing proto-
col consisted of 1 set of 10–12 repetitions at approxi-
mately 50% 1RM followed by 1 set of 2–3 repetitions atapproximate intensities of 75% and 85% 1RM. After the
final warm up set, weight was increased in 5-20 lb incre-
ments until 1RM was attained. 5RM determination
followed an identical pattern; however, intensities were
relative to 5RM instead of 1RM. These RM values were
used to calculate the load used for each exercise for each
participant. These exercises were also altered at week 5
to introduce a more novel stimulus. All participants
were required to perform the prescribed number of rep-
etitions with their prescribed weight. In the event that a
subject reached muscular failure, a laboratory researcher
assisted with the completion of the exercise. A compre-
hensive outline of the workouts can be found in Table 1.
Strength was assessed via 1-RM testing of the leg press
and bench press. Total strength was calculated as the
sum of both leg press and bench press. Body compo-
sition (lean body mass, fat mass, and total mass) was de-
termined on a Lunar Prodigy DXA apparatus (software
version, enCORE 2008, Madison, Wisconsin, U.S.A.).
Skeletal muscle hypertrophy was determined via changes
in CSA of the rectus femoris at 50% femur length while
the participant rested supine with a portable ultrasound
device (Logiq e, General Electric Medical Systems,
Milwaukee, WI, USA) in B mode with a wide-band lin-
ear array transducer (12 L-RS, General Electric Medical
Systems, Milwaukee, WI, USA) sampling at 12 MHz.
Ultrasound has previously been verified as a valid mea-
surement of CSA [21]. However in the present study, a
simpler, conventional method was used as opposed to
the panoramic method used by Ahtiainen et al. Using
the conventional method, a single image is captured for
subsequent measurement instead of combing several im-
ages along a path, as with panoramic. Femur length was
defined as the distance between the anterior superior
iliac spine and the superior aspect of the patella. Probe
placement was traced with permanent marker, and each
subject was instructed to reapply the mark daily. Ad-
ditionally, researchers affirmed and reapplied the mark
during each laboratory and resistance training visit.
Upon retesting, 50% femur length was remeasured to
assure the mark had not deviated. The average of the
greatest two out of three measurements was used to
CSA value. Power was assessed during a maximal cycling
ergometry test. During the cycling test, the volunteer was
instructed to cycle against a predetermined resistance
(7.5% of body weight) as fast as possible for 10 seconds
[22]. The saddle height was adjusted to the individual’s
height to produce a 5–10° knee flexion while the foot was
in the low position of the central void. A standardized ver-
bal stimulus was provided to the subjects. Power output
was recorded in real time by a computer connected to the
Monark standard cycle ergometer (Monark model 894e,
Vansbro, Sweden) during the 10-second sprint test. Peak
power (PP) was recorded using Monark Anaerobic test
Table 1 Workout program









restWeek 1-4 Week 4-8 Week 1-4 Week 4-8 Week 1-4 Week 4-8
Leg press Leg press Bent over row Pendlay row Leg press Leg press Week 1 12 5 45 s 3-5 m
Leg extension safety bar squat Barbell shrug Hexbar shrug Bench press Bench press Week 2 10 3 60s 3-5 m
Leg curl barbell lunge Straight arm pulldown Pulldown Leg extension Safety bar squat Week 3 8 2 90s 3-5 m
Hyperextion Stiff leg deadlift Australian row Decline dumbell row Close grip bench press Flat dumbell press Week 4 6 1 120 s 3-5 m
Bench press Bench press Barbell shoulder press Dumbell shoulder press Week 5 12 5 60s 3-5 m
Incline dumbell press Flat dumbell press Isolated barbell military Upright row Week 6 10 3 60s 3-5 m
Close grip bench press Cable crossover Dumbell lateral raise Barbell front raise Week 7 8 2 90s 3-5 m
Cable rope extensions Skull crushes Dumbell bicep curls Barbell bicep curls Week 8 6 1 120 s 3-5 m
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1.0, Monark, Vansbro, Sweden). From completion of
Wingate tests performed over several days, interclass cor-
relation coefficient for peak power was 0.96.
Two weeks prior to and throughout the study, subjects
were placed on a diet consisting of 25% protein, 50% car-
bohydrates, and 25% fat by a registered dietician who spe-
cialized in sport nutrition. Subjects met as a group with
the dietitian, and they were given individual meal plans at
the beginning of the study. Daily total of calories were de-
termined by the Harris Benedict equation and tracked by
weekly logs to ensure compliance. The PA group received
750 mg of soy-derived PA (Mediator®, Chemi Nutra,
White Bear Lake, MN) per day, while the PLA group re-
ceived 750 mg of rice flour, each delivered in 5 visually
identical capsules. On RT days, participants consumed
450 mg of their respective supplement 30 minutes prior to
RT and 300 mg immediately following RT with 24 g of hy-
drolyzed collagen protein powder from beef skin (Pepti-
plus XB agglomerated, Gelita AG, Eberbach, Germany)
mixed with 500 ml water. The protein supplement was
provided in order to ensure control for post-exercise
meals between groups and hydrolyzed collagen was
chosen as an incomplete protein source low in leucine
(3.2 weight%). On non-RT days, participants consumed
450 mg of their respective supplement with breakfast and
the remaining 300 mg with dinner. Participants were re-
quired to return to the laboratory with their empty bags
to ensure compliance. Post-study analysis of the subjects’
diet revealed that it consisted of 25% protein, 51% carbo-
hydrates, and 24% fat, with no differences between groups.
The PA group consumed 2,865 ± 271 Calories per day
(79.5 ± 6.7 g fat; 358.1 ± 28.6 g carbohydrate; 179.0 ±
15.0 g protein), and the PLA group consumed 2,795 ± 236
Calories per day (74.5 ± 5.4 g fat; 356.4 ± 32.1 g carbohy-
drate; 174.6 ± 12.9 g protein). Since the dietician had
weekly interaction with the subjects, all subjects remained
compliant throughout the study. Product formulations
were blinded to both the investigators and the volunteers
and coded so that neither knew which formulation was
consumed during each trial.
All participants were informed of all risks associated
with the study, and each participant signed an informed
consent prior to beginning the study. This investigation
was approved by the University’s Institutional Review
Board.
Statistics
Phase 1 data was analyzed using a one way analysis of
variance (ANOVA) for all data. A Tukey’s Multiple Com-
parison Test was used to determine significant differences
between treatments. Significance was set at P < 0.05. Sta-
tistical analyses were performed on SigmaStat software
(San Jose, CA, USA). A repeated measures ANOVA modelwas used to measure group, time, and group by time inter-
actions in phase 2. If any main effects were observed, a
Tukey post-hoc was employed to locate where differences
occurred. Data are presented as mean ± standard deviation.
All phase 2 statistics were run using Statistica software
(Statsoft, Tulsa, OK, USA).
Results
Cell culture tests
As shown in Figure 1, S-PI, S-PE, S-PC, DAG, and G3P
elicited no increase in the ratio of P-p70-389 to total p70
compared to vehicle stimulated cells. In contrast, elevated
mTOR signaling was observed at all tested concentrations
of S-PS (529, and 558%), E-PA (206, and 221%), S-LPA
(638, and 694%), and S-PA (658, and 636%; p < 0.05). In
addition, S-LPA and S-PA increased mTOR signaling to a
greater degree than did E-PA at all concentrations
(p < 0.05).
Body composition
No differences existed between groups at baseline for any
measure. There was a significant group x time effect
(p = 0.02) for CSA (Figure 2a), in which the PA group in-
creased (pre 4.5 ± 1.1 cm2, post 5.5 ± 1.3 cm2, Effect Size
(ES) = 0.92) to a greater extent than the PLA group (pre
4.5 ± 1.1 cm2, post 5.1 ± 1.2 cm2, ES = 0.52). There was
a significant group × time effect (p = 0.01) for LBM
(Figure 2b), in which the PA group increased to a greater
extent (pre 59.7 ± 6.0 kg, post 62.1 ± 5.5 kg, ES = 0.42)
than the PLA group (pre 59.5 ± 4.7 kg, post 60.7 ± 4.7 kg,
ES = 0.26). There was a significant time effect (p = 0.02)
for Total Body Mass (TBM) in which the PA group in-
creased from 78.1 ± 8.7 to 78.7 ± 7.9 kg and the PLA
group increased from 75.7 ± 5.8 to 76.5 ± 6.1 kg, but no
differences existed between groups (p = 0.71). There was a
significant time effect (p < 0.01) for fat mass (Figure 2c), in
which there was a trend (p = 0.068) for fat mass to de-
crease to a greater extent in the PA group (pre 15.1 ±
4.8 kg, post 13.8 ± 4.2 kg, ES = −0.28) than the PLA group
(pre 13.0 ± 6.5 kg, post 12.5 ± 6.9 kg, ES = −0.07).
Strength and power
There was a significant group x time effect (p < 0.05) for
leg press 1RM, in which the PA group increased to a
greater extent (pre 228.7 ± 49.5 kg, post 280.6 ± 36.2 kg,
ES = 1.2) than the PLA group (pre 226.3 ± 47.2 kg, post
258.7 ± 36.1 kg, ES = 0.78). There was a significant time
effect (p < 0.01) for bench press 1RM, in which both the
PA (pre 98.0 ± 13.5 kg, post 105.0 ± 12.4 kg, ES = 0.5)
and PLA (pre 91.4 ± 19.1 kg, post 96.1 ± 17.0 kg,
ES = 0.25) increased; however, no differences were
present between groups (p = 0.11). There was a signifi-
cant group x time effect (p < 0.05) for total strength, in
which the PA group increased to a greater extent (pre
Figure 1 The effect of various lipids on the activation of mTOR signaling. C2C12 myoblasts were stimulated for 20 minutes with vehicle
(Control), or 10-30 μM of soy-derived (S) phosphatidylserine (S-PS), phosphatidylinositol (S-PI), phosphatidyl-ethanolamine (S-PE), phosphatidylcholine
(S-PC), PA (S-PA), lysophosphatidic acid (S-LPA), diacylglycerol (DAG), glycerol-3-phosphate (G3P), or egg-derived PA (E-PA). The samples were then
subjected to Western blot analysis for p70 phosphorylated on the threonine 389 residue (p70-389) and total p70. The ratio of these signals was
calculated and used as a marker of mTOR signaling. Values in the graphs represent the mean + SEM and were obtained from 2–3 independent
experiments (n = 4–12/group). * Significantly different from control (p < 0.001). # Significantly different from E-PA within each respective dose (p< 0.001).
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PLA group (pre 318.3 ± 60.3, post 355.5 ± 48.4, ES = 0.68).
Change values for strength can be found in Figure 3.
There was a significant time effect (p < 0.01) for Wingate
peak power, which increased in the PA group from
760.5 ± 166.0 W to 822.8 ± 217.3 W and from 733.5 ±
105.8 to 797.3 ± 122.3 W in the PLA group; however,
there were no differences between groups (p = 0.97).
Discussion
The purpose of this study was to screen for the most
effective phospholipid based activator of mTOR sig-
naling and to investigate the effects of PA on human
skeletal muscle hypertrophy, LBM, strength, and power
when consumed during a RT program in a double-blind,
placebo-controlled design. Our hypotheses were that PA
supplementation would augment the increase in skeletal
muscle hypertrophy, strength, and power that is induced
by RT.
mTOR is a master regulator of cellular growth, and
PA is widely known to be involved in the regulation of
the mTOR pathway [13,20,23,24]. Specifically, our pre-
vious studies have determined that an increase in the
exogenous availability of C8 PA, or PA derived from egg,
is sufficient to induce a significant increase in mTOR
signaling [14]. Research by Lehman et al. reported the
effects of PA along with various other phospholipids in
their ability to induce p70 activity revealing that only PA
was sufficient to induce an increase in p70 activity [25].
However, phase one of the current study demonstrates
that not only is soy-derived PA sufficient, but soy-
derived LPA and S-PS can also stimulate a robustincrease in mTOR signaling. Moreover, these lipid spe-
cies were directly compared to the effectiveness of E-PA,
and the results demonstrated that, compared to egg-
derived lipids, all of these soy-derived lipids were more
potent agonists of mTOR signaling. This could be due
to the composition of the PA molecule. For instance,
Foster et al. have reported differing effects of PA based
upon the structure of its fatty acid components; wherein,
two saturated fatty acids promoted storage, yet one satu-
rated and one unsaturated fatty acid promoted signaling
[16]. Thus, the higher unsaturated fat content of soy
may explain these observations. This suggests that soy
derived PA, LPA, and PS are superior agonists of mTOR
signaling, and therefore, they appear to be suitable can-
didates for augmenting the effects of RT on muscle
mass. However, it should be noted that reacylation of PA
after absorption is dependent upon the nutritional status
of the individual, and therefore, the observed differences
between the sources of PA (egg and soy) may or may
not translate to the effects observed with oral adminis-
tration of PA.
PA can be generated by G3P, one de novo fatty acid,
and one fatty acid from the diet via a lysophosphatidic
acid acyltransferase (LPAAT) mediated mechanism, or by
phosphorylation of DAG via DAG kinase, or by hydrolysis
of PC through phospholipase D (PLD). Although PC,
DAG and G3P did not directly activate mTOR signaling
in our cell culture studies, it remains possible that chronic
oral administration could potentially increase PA pools by
acting as a substrate for PA synthesis. Consistent with this
possibility, previous studies have shown that certain phos-
pholipids can improve athletic performance [26]. For
Figure 2 Changes in body composition. a. PA significantly
improves the resistance training-induced increase in CSA following
8 weeks of periodized resistance training. Data presented are means
and standard deviations. (*denotes significantly different from pre,
# denotes significantly different from placebo). b. PA significantly
improves the resistance training-induced increase in LBM following
8 weeks of periodized resistance training. Data presented are means
and standard deviations. (*denotes significantly different from pre,
# denotes significantly different from placebo). c. PA and PLA both
experience significant fat loss following 8 weeks of periodized resistance
training. However, only a trend is observed between groups over time.
(*denotes significantly different from pre).
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induced declines in choline levels and PS by blunting exer-
cise induced increases in cortisol [27] and improving men-
tal performance under stress [28]. However, no study has
yet investigated the effects of long-term PS supplementa-
tion in combination with resistance exercise on potential
gains in muscular hypertrophy. It is also important to note
that although we have determined maximal mTOR activa-
tion in response to PA occurs at approximately 20 minutes,
this is only one time point, and activation prior to, or
following, 20 minutes could have been missed. Therefore,
future research should investigate additional time points,
as well as lower concentrations, as 10 μM appeared to be
a saturating dose.
Effects of PA supplementation on CSA and LBM
For decades, it has been well documented that RT leads
to increases in muscle mass [29]. However, the mecha-
nism for muscle hypertrophy due to a mechanical stimu-
lus has only just begun to be elucidated. Recent research
indicates that the lipid second messenger, PA, could be
at least partially responsible for translating the mecha-
nical stimulus of RT into the chemical signal for skeletal
muscle hypertrophy [23]. For example, research con-
ducted by O’Neil et al. [20] has demonstrated that the
PA content of the cell is increased following eccentric
contractions and this effect is associated with a robust
activation of mTOR signaling.
It is interesting to note that the endogenously produced
PA can directly bind to, and activate, mTOR signaling
which, in-turn, can promote an increase in protein synthe-
sis. These effects appear to be independent of the PI3K
and ERK signaling pathways [14,20]. However, exogenous
PA can also be hydrolyzed to LPA, which binds to the
LPA family of G-protein-coupled receptors. The binding
of LPA to these receptors results in a cascade of events
which stimulate the ERK signaling pathway and also in-
crease PLD activity within the cell [15]. The result is a
dual mediated increase in mTOR signaling via increased
PA content within the cell as well as via the activation of
the ERK signaling pathway [15]. Thus through the activa-
tion of multiple pathways, supplementing with PA could
Figure 3 Changes in muscular strength. Changes in muscle strength from pre to post intervention are indicated by 1-repetition maximum (1RM)
measurements of leg press and bench press. Total strength is calculated by the summation of the two measurements. (*denotes significantly different
from pre, # denotes significantly different from placebo).
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plain why we observed a greater increase in skeletal
muscle accretion when supplementing with PA.
While a pilot study [18] found that changes in LBM
were likely enhanced by PA supplementation, they did
not find as robust of an effect as the present study in
either the control or experimental conditions. For ex-
ample, their results found no significant change in LBM
in the placebo group (+0.1 kg LBM), and they found
smaller effects in the experimental group (+1.7 kg LBM)
compared to the present study. These findings may in-
dicate that the training stimulus was inadequate to
enhance LBM by itself, and it may indicate that changes
in LBM were primarily driven by the supplement itself.
It is also possible that these findings are the result of
unsupervised training as research demonstrates greater
increases in neuromuscular adaptations in supervised, as
compared to unsupervised, training [30]. In contrast, the
present study found increases in both LBM and hyper-
trophy in both the placebo and PA conditions. These
findings may indicate that skeletal muscle hypertrophy
was driven by both endogenous (training) and exo-
genous (PA supplementation) mechanisms. Therefore,
future research may be interested in examining the
effects of PA on muscle hypertrophy in the absence of a
RT stimulus. Additionally, subjects were administered a
collagen protein supplement in order to standardize for
post-exercise nutrition. It should be noted, however, that
there is a low leucine content in collagen protein. There-
fore, we posit that collagen supplementation likely had
minimal effects in stimulating training-induced responses
in strength and body composition, as leucine is primarilyresponsible for protein’s effects on muscle protein syn-
thesis [31]. We chose a collagen protein supplement to
minimize possible effects of protein supplementation.
Moreover while mTOR and P-p70-389 influence MPS,
MPS was not directly measured in this study, and this
mechanism for muscle hypertrophy must be validated in
future research.
It is interesting to note that there was a trend (p = 0.068)
for PA to decrease body fat (ES = 0.28). Past research
strongly suggests that RT alone does not provide a strong
stimulus for fat loss [32]. However since muscle mass is a
very metabolically active tissue [33], the fat loss may be ex-
plained by the increased LBM. While we presently can only
speculate as to why or if this may be the case, future re-
search may be interested in exploring the possibility of PA
as a fat loss agent, as PA is known to interact with many
complexes [34].
Strength and power
Strength is one of the most critical attributes underlying
success in sport [35,36]. The collective results of the
present study, as well as those from Hoffman [18], suggest
that changes in strength following supervised and non-
supervised RT are enhanced by PA supplementation. The
observed increases in skeletal muscle CSA certainly con-
tribute to the increases observed in strength, and as PA is
not expected to directly increase strength, we believe the
increases in strength are due to the increases in CSA,
which has been well documented [29]. Additionally, we
believe no differences were observed for power as the
participants did not train with a power-oriented stimulus.
Rather they trained for hypertrophy twice per week, and
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needed to determine if PA can enhance improvements in
power.
Conclusions
PA induces an increase in mTOR signaling in a cell cul-
ture model. Oral PA administration is capable of enhan-
cing the anabolic effects of resistance training and
contributes to muscle accretion over time. Oral PA sup-
plementation can directly augment changes in skeletal
muscle hypertrophy following a chronic RT stimulus and
results in significant increases in strength and LBM over
placebo.
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